First reported 13 hours ago -
Updated 13 hours ago -
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced new, primary endpoint
data from an ongoing, open-label, multicenter, randomized Phase 2 trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with myelodysplastic ...
[Published Street Insider - 13 hours ago]